-
The in vitro diagnostics market is expected to continue to grow, with the pharmaceutical company's net profit increasing by 278 times
Time of Update: 2022-09-26
70% year-on-year to 666 million yuan; and the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses increased by 648.
-
Under the tide of layoffs in pharmaceutical companies, the demand for professional talents is becoming more and more vigorous
Time of Update: 2022-09-26
Especially in recent years, with the normalization of collection and procurement, the continuous advancement of medical insurance control fees, and the decline in drug prices have become a trend, forcing enterprises to accelerate innovation and upgrading, and affected by this, many companies have begun to frequently lay off employees in order to cut costs, optimize structure, and focus on advantageous businesses.
-
This domestic 1 class 1 new hypoglycemic drug will break out and enter the era of blowout!
Time of Update: 2022-09-21
(SPC) has reached a preset endpoint in two key clinical trials of the new class 1 drug "plumaglistin tablets" (DBPR108 tablets) for the treatment of type 2 diabetes, and the Group intends to submit an application for pre-market communication to the State Food and Drug Administration of China in the near future.
-
Hengrui again ushered in the outbreak of more than 40 domestic exclusive new drugs to disrupt the trillion market
Time of Update: 2022-09-21
Hospital Hospital Erecib tablets are the earliest approved innovative drugs of Hengrui, with terminal sales of public medical institutions in China only about 80 million yuan in 2016 and the current peak sales of 930 million yuan in 2021.
-
The eighth batch of 16 antibacterial drugs was collected to prepare for the battle of Kelun and Beite
Time of Update: 2022-09-21
The eighth batch of collection of collection affects the nerves of the industry, as the key object of collection, the whole body with antibacterial drugs has 16 varieties to meet the conditions of 4,
-
Qinghai adjusted the charging prices of 1163 medical service items
Time of Update: 2022-09-21
(End)Pharmaceutical enterprises On the 13th, the reporter learned from the press conference on the "Qinghai Decade" medical insurance work held by the Information Office of the Qinghai Provincial Government on the same day that in order to continue to promote the reform of centralized recruitment of pharmaceutical consumables, Qinghai Province completely cancelled the bonus of drugs and medical consumables in public medical institutions, and the burden of medical treatment for the people was further reduced.
-
In the first half of 2022, the sales costs of many pharmaceutical companies were reduced
Time of Update: 2022-09-21
Among them, 7 companies, including BeiGene, Hengrui, Junshi Biological, China Biopharmaceuticals, CSPC Pharmaceutical Research and Development, and Huang Pharmaceutical, have invested more than 1 billion yuan.
Among them, 7 companies, including BeiGene, Hengrui, Junshi Biological, China Biopharmaceuticals, CSPC Pharmaceutical Research and Development, and Huang Pharmaceutical, have invested more than 1 billion yuan.
-
Three major points of price control for dental implant medical services!
Time of Update: 2022-09-21
Oral implants "sky-high fees", low-cost implant advertisements to deceive patients, "benefit fees" and "introduction fees" to buy customers. . . In recent years, the demand for dental implants in Chi
-
In 2022, the market size of innovative drugs will exceed 1,000 billion yuan
Time of Update: 2022-09-21
Affected by multiple resonances such as favorable policies, capital increases, and talent returns, the domestic innovative drug industry has developed rapidly in recent years, and the market size has been expanding, from 799 billion yuan in 2017 to 963.
-
Salary increase! In the first half of the year, the average salary of R&D personnel of a large number of pharmaceutical companies increased
Time of Update: 2022-09-21
At the same time, there is also a situation that in the first half of the year, the average salary of R&D personnel of a large number of pharmaceutical companies has increased, such as BeiGene, Yahong Pharmaceutical, Haoyuan Pharmaceutical, Zejing Pharmaceutical, Rongchang Biologics, BIO and other companies at least more than 20 companies have a certain growth, the increase range of 1% to 87%.
-
Since the beginning of this year, a large number of multinational pharmaceutical companies have failed clinically in tumor immunotherapy!
Time of Update: 2022-09-21
The industry believes that from the above, although the market prospects for tumor immunotherapy drugs brought about by favorable policies and capital increases are becoming more and more broad in recent years, the examples of the failure of new drug research and development of these multinational pharmaceutical companies are constantly warning everyone that even if they go through phase I and phase II clinical trials, they may also encounter challenges in phase III.
-
The heavy sales model of pharmaceutical companies has changed, and the sales expenses of 5 pharmaceutical companies in the first half of the year have dropped by more than 30% year-on-year.
Time of Update: 2022-09-21
Among them, China Traditional Chinese Medicine, Yingke Medical, Ruikang Pharmaceutical, North China Pharmaceutical, Hengrui, these 5 pharmaceutical companies, although the sales costs in the first half of the year were more than 100 million yuan, but the year-on-year decline has exceeded 30%.
-
What signal is released by the accelerated withdrawal of capital from pharmaceutical companies?
Time of Update: 2022-09-21
According to the semi-annual report, BGI's net cash flow from operating activities was -225 million yuan, a year-on-year decrease of 133.
According to the semi-annual report, BGI's net cash flow from operating activities was -225 million yuan, a year-on-year decrease of 133.
-
Injection consistency evaluation TOP10: Yangtze River, Kelun, Qilu lead
Time of Update: 2022-09-21
Just into September, more than 10 injections (in terms of drug name + group) have passed or are deemed to have passed the consistency evaluation. According to the data of the Intranet, the current ev
-
The chain rate continues to increase, and a large number of single pharmacies will disappear!
Time of Update: 2022-09-21
Among them, according to the high-quality development construction goal of "retail chain rate of nearly 70%" in 2025, with 606,500 pharmacies as the base, the number of stores of single pharmacies will be reduced to about 180,000 in the next three years, compared with about 250,000 now, or a sharp decrease of about 70,000.
-
16 kinds of proprietary Chinese medicines are facing the alliance collection! Or good for the head enterprise
Time of Update: 2022-09-21
The industry believes that from the perspective of the 16 kinds of proprietary Chinese medicines selected in this collection, they are all more representative and clinically used varieties, which can achieve price for volume, and also have more value of quality assurance, and it is expected that the competition of enterprises in the collection and procurement negotiations will be more intense.
-
The modernization and development of the Chinese medicine industry is the trend of the times, but the challenges still exist, how to deal with it?
Time of Update: 2022-09-21
It is understood that with the rapid development of the Internet, the Internet of Things, intelligent manufacturing and other technologies, in recent years, these new technologies are playing an important role in the planting, processing and production, traceability, distribution and other aspects of Chinese herbal medicines, and promoting industrial innovation and upgrading.
-
The 300 billion retail market is making waves again! 46 varieties nugget new tracks
Time of Update: 2022-09-21
In order to meet the needs of clinical drugs and standardized drug management, since 2004, the State Food and Drug Administration has converted 805 prescription drugs into over-the-counter drugs, inc
-
The price of sour jujube kernels has risen by more than 1,000 yuan, is it a curse caused by artificial speculation?
Time of Update: 2022-09-21
Hebei sour jujube kernel dealers introduced that the local production has entered the middle stage, there have not been a large number of new goods into the market, the price of sour jujube fresh goods rose from 13 yuan on August 15 to the current 20 yuan, resulting in a large increase in farmers' enthusiasm for harvesting.
-
Many places are vigorously promoting the special rectification of online drug sales!
Time of Update: 2022-09-21
In addition, the Measures for the Supervision and Administration of Online Drug Sales (hereinafter referred to as the Measures) issued by the State Administration for Market Regulation will be implemented from December 1, 2022.
